Masoud Kargar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Masoud Kargar has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ali Hashemi
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 shared publications - Javad Yasbolaghi Sharahi
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications Bijan Keikhaei
Thalassemia and Hemoglobinopathy Research Center, Health Research Institute Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
2 shared publications- Mehdi Goudarzi
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Mohammad Ali Jalali Far
Thalassemia & Hemoglobinopathy Research Center, Health Research Institute Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
2 shared publications Najmaldin Saki
Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 4479031
A Review of β ‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications
β ‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β ‐lactamase enzymes. The proliferation of these enzymes represents a critical threat to global public health, compounding therapeutic challenges and escalating healthcare costs. As the efficacy of conventional treatments diminishes, reliance on last‐resort agents like carbapenems and colistin has increased, in turn accelerating resistance to these precious final‐line options. To address this escalating crisis, the strategic combination of β ‐lactam antibiotics with β ‐lactamase inhibitors (BLIs) has emerged as a vital therapeutic approach, restoring the activity of β ‐lactams by inactivating the resistance enzymes. Since the introduction of clavulanic acid, significant progress has been made in expanding the BLI arsenal. This review provides a comprehensive analysis of the current landscape of novel BLIs that have been approved or are in advanced clinical development, delving into their distinct mechanisms of action, spectra of activity against Ambler molecular classes (A, B, C, and D), and evolving clinical applications. While early inhibitors primarily targeted serine‐ β ‐lactamases (SBLs), recent advancements have introduced agents with expanded profiles, including those effective against some Class D carbapenemases. A paramount, ongoing challenge remains the development of effective inhibitors against metallo‐ β ‐lactamases (MBLs), though promising candidates like taniborbactam and xeruborbactam are now in clinical development. This review synthesizes the current knowledge on these innovative inhibitors, from recently approved combinations like ceftazidime/avibactam and cefepime/enmetazobactam to those in advanced clinical trials, and critically examines the associated therapeutic challenges, including the emergence of resistance. By integrating mechanistic insights with clinical perspectives, this article is aimed at informing the ongoing battle against antimicrobial resistance and guiding the future development of life‐saving therapeutic strategies.
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 4479031
Open AccessA Review of β ‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications
β ‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β ‐lactamase enzymes. The proliferation of these enzymes represents a critical threat to global public health, compounding therapeutic challenges and escalating healthcare costs. As the efficacy of conventional treatments diminishes, reliance on last‐resort agents like carbapenems and colistin has increased, in turn accelerating resistance to these precious final‐line options. To address this escalating crisis, the strategic combination of β ‐lactam antibiotics with β ‐lactamase inhibitors (BLIs) has emerged as a vital therapeutic approach, restoring the activity of β ‐lactams by inactivating the resistance enzymes. Since the introduction of clavulanic acid, significant progress has been made in expanding the BLI arsenal. This review provides a comprehensive analysis of the current landscape of novel BLIs that have been approved or are in advanced clinical development, delving into their distinct mechanisms of action, spectra of activity against Ambler molecular classes (A, B, C, and D), and evolving clinical applications. While early inhibitors primarily targeted serine‐ β ‐lactamases (SBLs), recent advancements have introduced agents with expanded profiles, including those effective against some Class D carbapenemases. A paramount, ongoing challenge remains the development of effective inhibitors against metallo‐ β ‐lactamases (MBLs), though promising candidates like taniborbactam and xeruborbactam are now in clinical development. This review synthesizes the current knowledge on these innovative inhibitors, from recently approved combinations like ceftazidime/avibactam and cefepime/enmetazobactam to those in advanced clinical trials, and critically examines the associated therapeutic challenges, including the emergence of resistance. By integrating mechanistic insights with clinical perspectives, this article is aimed at informing the ongoing battle against antimicrobial resistance and guiding the future development of life‐saving therapeutic strategies.
- Open Access
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1)
An Investigation of Colistin Heteroresistance in Klebsiella pneumoniae Isolates in Iran
Background: According to the World Health Organization 2024 bacterial priority pathogens list, carbapenem‐resistant Enterobacterales (CRE) were listed among the critical priority pathogens. Heteroresistance (i.e., a bacterial isolate that appears susceptible but harbors resistant subpopulations) represents a challenge in traditional laboratory testing, which may lead to treatment failure with colistin. This phenomenon has been studied in many bacteria, including K. pneumoniae . To our knowledge, this is the first report of colistin heteroresistance in K. pneumoniae isolates using population analysis profiles (PAPs) in Iran. Methods: Between 2019 and 2020, 100 K. pneumoniae isolates were collected from various samples of hospitalized patients in Iran. This study primarily determined antibiotic resistance by antimicrobial susceptibility testing. Thereafter, the prevalence of colistin heteroresistance in K. pneumoniae isolates was evaluated by the PAP test. Heteroresistant isolates were typed by multilocus sequence typing (MLST). Results: The MIC test showed that 79 (79%) of the 100 K. pneumoniae isolates were susceptible to colistin. Overall, 2/79 colistin‐susceptible isolates were classified as heteroresistant isolates by the PAP method, with a colistin MIC of 0.5 μ g/ml. Importantly, after 5 serial passaging on colistin‐free plates, there was no increase in the MIC of the colistin‐resistant subpopulations, showing that heteroresistance cases were unstable. MLST revealed that heteroresistant isolates belong to ST377 and ST15. Conclusions: In conclusion, the current study contributes to our understanding of the challenges posed by heteroresistant isolates in clinical laboratories. Since heteroresistant isolates may be misidentified as susceptible by standard tests, these findings raise concerns regarding the interpretation of colistin susceptibility results.
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1)
Open AccessAn Investigation of Colistin Heteroresistance in Klebsiella pneumoniae Isolates in Iran
Background: According to the World Health Organization 2024 bacterial priority pathogens list, carbapenem‐resistant Enterobacterales (CRE) were listed among the critical priority pathogens. Heteroresistance (i.e., a bacterial isolate that appears susceptible but harbors resistant subpopulations) represents a challenge in traditional laboratory testing, which may lead to treatment failure with colistin. This phenomenon has been studied in many bacteria, including K. pneumoniae . To our knowledge, this is the first report of colistin heteroresistance in K. pneumoniae isolates using population analysis profiles (PAPs) in Iran. Methods: Between 2019 and 2020, 100 K. pneumoniae isolates were collected from various samples of hospitalized patients in Iran. This study primarily determined antibiotic resistance by antimicrobial susceptibility testing. Thereafter, the prevalence of colistin heteroresistance in K. pneumoniae isolates was evaluated by the PAP test. Heteroresistant isolates were typed by multilocus sequence typing (MLST). Results: The MIC test showed that 79 (79%) of the 100 K. pneumoniae isolates were susceptible to colistin. Overall, 2/79 colistin‐susceptible isolates were classified as heteroresistant isolates by the PAP method, with a colistin MIC of 0.5 μ g/ml. Importantly, after 5 serial passaging on colistin‐free plates, there was no increase in the MIC of the colistin‐resistant subpopulations, showing that heteroresistance cases were unstable. MLST revealed that heteroresistant isolates belong to ST377 and ST15. Conclusions: In conclusion, the current study contributes to our understanding of the challenges posed by heteroresistant isolates in clinical laboratories. Since heteroresistant isolates may be misidentified as susceptible by standard tests, these findings raise concerns regarding the interpretation of colistin susceptibility results.
- Open Access
- 27 December 2025
- Published by Wiley in Health Science Reports
- Vol. 9 (1) , e71648
Association of IL28B Polymorphisms With Hepatitis C Susceptibility in Southern Iran's β‐Thalassemia Population: A Cross‐Sectional Study
Background and Aims: Thalassemia is a hereditary hematological condition which interferes with the production of hemoglobin (Hb). Patients with thalassemia require regular blood transfusion, which makes them highly susceptible to pathogens, and especially viral pathogens. Hepatitis C virus (HCV) is also a big threat in that it is hepatotropic in nature and has the potential of causing hepatic injury. Host genetic factors, such as single nucleotide polymorphisms (SNPs) in the IFN λ3 (IL28B) gene, influence the ability to clear the virus and respond to therapy. In this research, we aimed to determine the frequency of the rs8099917 and rs12979860 polymorphisms of the IL28B gene in HCV‐infected thalassemia patients from southern Iran. Methods: Sixty‐five people with β‐thalassemia were recruited, including 25 people who are HCV positive and 40 people who are HCV negative. The genotyping of the locus at the rs8099917 and rs12979860 sites was done using the tetra‐primer amplification refractory mutation system‐polymerase chain reaction (T‐ARMS‐PCR). Results: On analyzing the locus at rs8099917, we noted that the TT genotype was common among patients who had HCV, with the proportion of 72% versus 12.5% among HCV‐negative individuals. The GG genotype was also rare in the HCV‐positive group and not present in the HCV‐negative group. On the other hand, TG genotype were found in 20% of the HCV‐positive patients with 87.5% of the HCV‐negative subjects, presenting a very significant difference ( p < 0.001). On the other hand, the distribution of the rs12979860 genotype was not significantly different in the two groups. Conclusion: Our findings suggest that the rs8099917 SNP of the IL28B gene may serve as a useful baseline predictor of antiviral responses in thalassemia patients infected with HCV.
- 27 December 2025
- Published by Wiley in Health Science Reports
- Vol. 9 (1) , e71648
Open AccessAssociation of IL28B Polymorphisms With Hepatitis C Susceptibility in Southern Iran's β‐Thalassemia Population: A Cross‐Sectional Study
Background and Aims: Thalassemia is a hereditary hematological condition which interferes with the production of hemoglobin (Hb). Patients with thalassemia require regular blood transfusion, which makes them highly susceptible to pathogens, and especially viral pathogens. Hepatitis C virus (HCV) is also a big threat in that it is hepatotropic in nature and has the potential of causing hepatic injury. Host genetic factors, such as single nucleotide polymorphisms (SNPs) in the IFN λ3 (IL28B) gene, influence the ability to clear the virus and respond to therapy. In this research, we aimed to determine the frequency of the rs8099917 and rs12979860 polymorphisms of the IL28B gene in HCV‐infected thalassemia patients from southern Iran. Methods: Sixty‐five people with β‐thalassemia were recruited, including 25 people who are HCV positive and 40 people who are HCV negative. The genotyping of the locus at the rs8099917 and rs12979860 sites was done using the tetra‐primer amplification refractory mutation system‐polymerase chain reaction (T‐ARMS‐PCR). Results: On analyzing the locus at rs8099917, we noted that the TT genotype was common among patients who had HCV, with the proportion of 72% versus 12.5% among HCV‐negative individuals. The GG genotype was also rare in the HCV‐positive group and not present in the HCV‐negative group. On the other hand, TG genotype were found in 20% of the HCV‐positive patients with 87.5% of the HCV‐negative subjects, presenting a very significant difference ( p < 0.001). On the other hand, the distribution of the rs12979860 genotype was not significantly different in the two groups. Conclusion: Our findings suggest that the rs8099917 SNP of the IL28B gene may serve as a useful baseline predictor of antiviral responses in thalassemia patients infected with HCV.
- Open Access
- 19 December 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
The emerging role of non-coding RNAs in the pathogenesis of infantile hemangioma
Infantile hemangioma (IH) is a common benign tumor that occurs in children, affecting both blood vessels and soft tissues. Its pathological features includ
- 19 December 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
Open AccessThe emerging role of non-coding RNAs in the pathogenesis of infantile hemangioma
Infantile hemangioma (IH) is a common benign tumor that occurs in children, affecting both blood vessels and soft tissues. Its pathological features includ
- 18 November 2025
- Published by Springer Nature in Current Microbiology
- Vol. 83 (1) , 25
Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance
The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly carbapenem- and colistin-resistant strains, represents a critical public health crisis with limited therapeutic options. Cefiderocol, a first-in-class siderophore cephalosporin, addresses this challenge through an innovative Trojan horse mechanism. Its unique catechol-containing C-3 side chain enables iron chelation and active transport into bacterial periplasmic space, bypassing traditional resistance pathways. This design confers stability against all Ambler class β-lactamases (A-D), including carbapenemases (blaKPC, blaOXA-48, blaNDM, blaVIM, and blaIMP), and maintains potent activity against MDR Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia. While clinical trials demonstrate efficacy in complicated urinary tract infections, hospital-acquired pneumonia, and bloodstream infections, emerging resistance and mortality signals in specific populations warrant careful consideration. This comprehensive review examines cefiderocol’s molecular structure, mechanisms of action and resistance, pharmacokinetic profile, and clinical applications. We evaluate its position relative to newer β-lactam/β-lactamase inhibitors and explore evidence for combination therapies, ultimately highlighting its crucial role in the antimicrobial arsenal against MDR Gram-negative infections.
- 18 November 2025
- Published by Springer Nature in Current Microbiology
- Vol. 83 (1) , 25
Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance
The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly carbapenem- and colistin-resistant strains, represents a critical public health crisis with limited therapeutic options. Cefiderocol, a first-in-class siderophore cephalosporin, addresses this challenge through an innovative Trojan horse mechanism. Its unique catechol-containing C-3 side chain enables iron chelation and active transport into bacterial periplasmic space, bypassing traditional resistance pathways. This design confers stability against all Ambler class β-lactamases (A-D), including carbapenemases (blaKPC, blaOXA-48, blaNDM, blaVIM, and blaIMP), and maintains potent activity against MDR Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia. While clinical trials demonstrate efficacy in complicated urinary tract infections, hospital-acquired pneumonia, and bloodstream infections, emerging resistance and mortality signals in specific populations warrant careful consideration. This comprehensive review examines cefiderocol’s molecular structure, mechanisms of action and resistance, pharmacokinetic profile, and clinical applications. We evaluate its position relative to newer β-lactam/β-lactamase inhibitors and explore evidence for combination therapies, ultimately highlighting its crucial role in the antimicrobial arsenal against MDR Gram-negative infections.
- Open Access
- 18 March 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (3) , 1493-1499
Association between HLA-DRB1*04, HLA-DQB1*03, and HLA-DQB1*06 with alloimmunization in transfusion-dependent patients with thalassemia: the first case-control study in Iran
Transfusion therapy is crucial for treating Transfusion-dependent thalassemia (TDT) patients. However, the production of Alloantibodies presents a substantial challenge for these individuals and impacts their quality of life. The Rh and Kell blood group antigens are particularly susceptible to alloantibody development. This study aims to establish the correlation between HLA-DRB1*04, HLA-DQB1*03, and HLA-DQB1*06 alleles and alloimmunzation in thalassemia patients from Iran. 98 thalassemic patients were recruited for this study (49 alloimmunized and 49 non-alloimmunized). Alloimmunized patients developed Rh and Kell specificities alloantibodies. The two groups were compared based on the results of HLA-DRB1 and HLA-DQB1 genotyping conducted using Sequence-Specific Primers (SSP-PCR). The findings from the antibody screening revealed that the predominant alloantibody detected was Anti-K (95.9%), Anti-E (65.3%), Anti-C (30.6%), Anti-D (28.6%), Anti-c (10.2%), Anti-e (2%), and Anti-k (2%). There was a notable difference in HLA-DQB1*03 between alloimmunized and non-alloimmunized groups, 41.8% vs. 58.2%, respectively. (iP = 0.001, OR = 0.135, CI = 0.036–0.499). There was not any notable relationship between HLA-DRB1*04 and HLA-DQB1*06 alleles and alloimmunization. Our findings indicate that HLA-DQB1*03 may have a protective role in preventing alloantibody production. Thus, HLA-typing, particularly focusing on DQB1*03, can significantly enhance the screening process, leading to improved blood transfusion management, reduced rejection of hematopoietic stem cell transplantation, and minimized blood transfusion complications.
- 18 March 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (3) , 1493-1499
Open AccessAssociation between HLA-DRB1*04, HLA-DQB1*03, and HLA-DQB1*06 with alloimmunization in transfusion-dependent patients with thalassemia: the first case-control study in Iran
Transfusion therapy is crucial for treating Transfusion-dependent thalassemia (TDT) patients. However, the production of Alloantibodies presents a substantial challenge for these individuals and impacts their quality of life. The Rh and Kell blood group antigens are particularly susceptible to alloantibody development. This study aims to establish the correlation between HLA-DRB1*04, HLA-DQB1*03, and HLA-DQB1*06 alleles and alloimmunzation in thalassemia patients from Iran. 98 thalassemic patients were recruited for this study (49 alloimmunized and 49 non-alloimmunized). Alloimmunized patients developed Rh and Kell specificities alloantibodies. The two groups were compared based on the results of HLA-DRB1 and HLA-DQB1 genotyping conducted using Sequence-Specific Primers (SSP-PCR). The findings from the antibody screening revealed that the predominant alloantibody detected was Anti-K (95.9%), Anti-E (65.3%), Anti-C (30.6%), Anti-D (28.6%), Anti-c (10.2%), Anti-e (2%), and Anti-k (2%). There was a notable difference in HLA-DQB1*03 between alloimmunized and non-alloimmunized groups, 41.8% vs. 58.2%, respectively. (iP = 0.001, OR = 0.135, CI = 0.036–0.499). There was not any notable relationship between HLA-DRB1*04 and HLA-DQB1*06 alleles and alloimmunization. Our findings indicate that HLA-DQB1*03 may have a protective role in preventing alloantibody production. Thus, HLA-typing, particularly focusing on DQB1*03, can significantly enhance the screening process, leading to improved blood transfusion management, reduced rejection of hematopoietic stem cell transplantation, and minimized blood transfusion complications.
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Microbiology
- Vol. 2025 (1)
Detection of Colistin Heteroresistance in Carbapenem‐Resistant Pseudomonas aeruginosa Clinical Isolates in Iran
Background: Since antimicrobial resistance is a rising danger and a serious threat to the health of humans, recent studies have revealed that routine tests, such as minimum inhibitory concentration (MIC), are not enough to detect heteroresistance (HR) phenotype (i.e., phenotypic heterogeneity in antibiotic susceptibility in the identical bacterial population), and medical laboratories require awareness raising to face it. Colistin is regarded as the final therapeutic option for infections caused by carbapenem‐resistant gram‐negative bacteria. In this study, we explored the presence of HR to colistin in carbapenem‐resistant Pseudomonas aeruginosa isolates in Iran. Methods: From 2019 to 2020, 100 P. aeruginosa clinical isolates were gathered from hospitals in various regions in Iran. In the present study, antibiotic susceptibility testing was used to determine antibiotic resistance. The population analysis profile (PAP) test was conducted to measure HR. Additionally, PCR was carried out to detect metallo‐ β ‐lactamase genes, including bla NDM-1 and bla IMP , and bla VIM genes of colistin heteroresistant isolates. Results: As a result, of the 100 P. aeruginosa isolates that were tested by AST, 66 were resistant to carbapenem antibiotics. Here, we found that 62 carbapenem‐resistant Pseudomonas aeruginosa (CRPA) isolates were susceptible to colistin, while four isolates were resistant to colistin. Regarding the PAP assay, we identified eight heteroresistant isolates, of which three and two isolates carried bla NDM-1 and bla IMP genes, respectively. Furthermore, the HR isolates demonstrated a stable phenotype after seven subcultures in Mueller Hinton agar (MHA) without antibiotics. Conclusions: Finally, our study highlights the interplay between HR and its diagnosis methods. Since it is difficult to detect heteroresistant isolates by routine tests in clinical laboratories, it might be misclassified as susceptible and lead to challenges for clinicians and their patients.
- 1 January 2025
- Published by Wiley in International Journal of Microbiology
- Vol. 2025 (1)
Open AccessDetection of Colistin Heteroresistance in Carbapenem‐Resistant Pseudomonas aeruginosa Clinical Isolates in Iran
Background: Since antimicrobial resistance is a rising danger and a serious threat to the health of humans, recent studies have revealed that routine tests, such as minimum inhibitory concentration (MIC), are not enough to detect heteroresistance (HR) phenotype (i.e., phenotypic heterogeneity in antibiotic susceptibility in the identical bacterial population), and medical laboratories require awareness raising to face it. Colistin is regarded as the final therapeutic option for infections caused by carbapenem‐resistant gram‐negative bacteria. In this study, we explored the presence of HR to colistin in carbapenem‐resistant Pseudomonas aeruginosa isolates in Iran. Methods: From 2019 to 2020, 100 P. aeruginosa clinical isolates were gathered from hospitals in various regions in Iran. In the present study, antibiotic susceptibility testing was used to determine antibiotic resistance. The population analysis profile (PAP) test was conducted to measure HR. Additionally, PCR was carried out to detect metallo‐ β ‐lactamase genes, including bla NDM-1 and bla IMP , and bla VIM genes of colistin heteroresistant isolates. Results: As a result, of the 100 P. aeruginosa isolates that were tested by AST, 66 were resistant to carbapenem antibiotics. Here, we found that 62 carbapenem‐resistant Pseudomonas aeruginosa (CRPA) isolates were susceptible to colistin, while four isolates were resistant to colistin. Regarding the PAP assay, we identified eight heteroresistant isolates, of which three and two isolates carried bla NDM-1 and bla IMP genes, respectively. Furthermore, the HR isolates demonstrated a stable phenotype after seven subcultures in Mueller Hinton agar (MHA) without antibiotics. Conclusions: Finally, our study highlights the interplay between HR and its diagnosis methods. Since it is difficult to detect heteroresistant isolates by routine tests in clinical laboratories, it might be misclassified as susceptible and lead to challenges for clinicians and their patients.
- Open Access
- 30 June 2024
- Published by Maad Rayan Publishing Company in Avicenna Journal of Clinical Microbiology and Infection
- Vol. 11 (2) , 82-86
A Study of Antimicrobial Resistance Rates in Clinical Burn Center Isolates of Pseudomonas aeruginosa in the South of Iran
Background: This research aimed to examine the frequency of resistance to antimicrobial agents and their variations in Pseudomonas aeruginosa clinical isolates, which are accountable for invasive infections in the southern part of Iran, from 2018 to 2022. Methods: A retrospective study was conducted, involving the gathering of microbiological data from Taleghani Burn Hospital from 2018 to 2022. The primary variables under scrutiny were department, sample origin, the antiprogram system (e.g., disc diffusion and strip methods, and clinical laboratory standards), and the rate or percentage of resistant isolates investigated by antimicrobial susceptibility testing. The interpretation criteria employed for the study were those of the Clinical Laboratory Standards Institute (CLSI). And the percentage of resistant isolates was also taken into consideration. Results: The disc diffusion and strip method is the most commonly used approach for antimicrobial susceptibility testing. According to the CLSI, resistance rates ranged from 3.64% (colistin) to 77.38% (amikacin). The rates of antimicrobial resistance remained relatively constant over time in 2018-2022. Approximately 67.62% of isolates were multidrug resistant, and the remaining 9.46% were extensively drug-resistant. Wound and urine isolates demonstrated higher resistance, except for amikacin and piperacillin, than those from blood culture and biopsy. Conclusion: Antimicrobial resistance is widely prevalent in P. aeruginosa, a common bacterium in southern Iran. The findings revealed the highest resistance rates for commonly used antibiotics such as amikacin, piperacillin, ceftazidime, and meropenem. However, colistin and nitrofurantoin are more effective against this bacterium. The wound and urine isolates represented the highest resistance rates, indicating the need for prompt and appropriate treatment. Interestingly, the resistance rates for most antibiotics remained relatively stable during the study period, emphasizing the need to develop alternative treatments for P. aeruginosa infections.
- 30 June 2024
- Published by Maad Rayan Publishing Company in Avicenna Journal of Clinical Microbiology and Infection
- Vol. 11 (2) , 82-86
Open AccessA Study of Antimicrobial Resistance Rates in Clinical Burn Center Isolates of Pseudomonas aeruginosa in the South of Iran
Background: This research aimed to examine the frequency of resistance to antimicrobial agents and their variations in Pseudomonas aeruginosa clinical isolates, which are accountable for invasive infections in the southern part of Iran, from 2018 to 2022. Methods: A retrospective study was conducted, involving the gathering of microbiological data from Taleghani Burn Hospital from 2018 to 2022. The primary variables under scrutiny were department, sample origin, the antiprogram system (e.g., disc diffusion and strip methods, and clinical laboratory standards), and the rate or percentage of resistant isolates investigated by antimicrobial susceptibility testing. The interpretation criteria employed for the study were those of the Clinical Laboratory Standards Institute (CLSI). And the percentage of resistant isolates was also taken into consideration. Results: The disc diffusion and strip method is the most commonly used approach for antimicrobial susceptibility testing. According to the CLSI, resistance rates ranged from 3.64% (colistin) to 77.38% (amikacin). The rates of antimicrobial resistance remained relatively constant over time in 2018-2022. Approximately 67.62% of isolates were multidrug resistant, and the remaining 9.46% were extensively drug-resistant. Wound and urine isolates demonstrated higher resistance, except for amikacin and piperacillin, than those from blood culture and biopsy. Conclusion: Antimicrobial resistance is widely prevalent in P. aeruginosa, a common bacterium in southern Iran. The findings revealed the highest resistance rates for commonly used antibiotics such as amikacin, piperacillin, ceftazidime, and meropenem. However, colistin and nitrofurantoin are more effective against this bacterium. The wound and urine isolates represented the highest resistance rates, indicating the need for prompt and appropriate treatment. Interestingly, the resistance rates for most antibiotics remained relatively stable during the study period, emphasizing the need to develop alternative treatments for P. aeruginosa infections.